GlassScriptPhysician profile
Daniel Joseph Meshoto
NPI 1558334847
$7,720.99
in general payments reported to CMS, 2019-2025
28 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $928 · 2021: $1,555 · 2022: $802 · 2023: $953 · 2024: $1,275 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,071.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,155.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,016.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $469.10 | 2019-2025 | Freestyle Libre 3 |
| Alkermes, INC. | $332.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $278.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.35 | 2019-2023 | Jardiance |
| Pfizer INC. | $239.77 | 2019-2025 | |
| Amgen INC. | $239.76 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $236.61 | 2023-2025 | Arexvy, Shingrix |
| Allergan, INC. | $179.07 | 2019-2020 | |
| Abbvie INC. | $166.70 | 2021 | |
| Eisai INC. | $159.13 | 2020-2021 | |
| Procept Biorobotics Corporation | $157.03 | 2024 | Aquabeam System |
| Amarin Pharma, INC. | $138.15 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $121.81 | 2023 | Quviviq |
| Exact Sciences Corporation | $99.07 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $94.69 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.93 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.86 | 2019-2021 | |
| Antares Pharma, INC. | $45.35 | 2020 | |
| Phathom Pharmaceuticals, INC. | $34.99 | 2024 | Voquezna |
| Aytu Biopharma, INC. | $26.03 | 2019 | |
| Tactile Systems Technology INC | $19.88 | 2025 | Nimbl, Flexitouch Plus |
| Optos, INC. | $15.74 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.31 | 2021 | |
| Medtronic, INC. | $15.17 | 2022 | |
| Neuronetics, INC. | $10.28 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Meshoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.